Literature DB >> 16494654

Headache induced by dopamine agonists prescribed for prolactinoma: think SUNCT!

A J Larner1.   

Abstract

Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) syndrome may be associated with pituitary prolactinoma and may be induced by treatment of prolactinoma with dopamine agonists. Endocrinologists treating patients with prolactinoma need to be aware of this syndrome as its pathophysiology and treatment differ from that of other headache syndromes.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16494654     DOI： 10.1111/j.1368-5031.2005.00758.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN： 1368-5031            Impact factor:   2.503


  6 in total

Review 1.  How to investigate and treat: headache and hyperprolactinemia.

Authors:  Gennaro Bussone; Susanna Usai; Franca Moschiano
Journal:  Curr Pain Headache Rep       Date:  2012-08

Review 2.  Clinical Presentation and Management of Headache in Pituitary Tumors.

Authors:  Himanshu Suri; Carrie Dougherty
Journal:  Curr Pain Headache Rep       Date:  2018-06-15

3.  SUNCT and SUNA: Recognition and Treatment.

Authors:  Juan A Pareja; Mónica Alvarez; Teresa Montojo
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

4.  Cluster headache secondary to macroprolactinoma with ipsilateral cavernous sinus invasion.

Authors:  M J Levy; I Robertson; T A Howlett
Journal:  Case Rep Neurol Med       Date:  2012-09-23

5.  Prolactinoma Presenting as Short-lasting Unilateral Neuralgiform Headache Attacks with Conjunctival Injection and Tearing Syndrome.

Authors:  Swayamsidha Mangaraj; Pratap Kumar Mishra; Arun Kumar Choudhury; Binoy Kumar Mohanty; Anoj Kumar Baliarsinha
Journal:  J Neurosci Rural Pract       Date:  2017-08

6.  Botulinum Toxin A for the Treatment of a Child with SUNCT Syndrome.

Authors:  Yi Zhang; Haifeng Zhang; Ya-Jun Lian; Yun-Qing Ma; Nan-Chang Xie; Xuan Cheng; Lu Zhang
Journal:  Pain Res Manag       Date:  2016-04-06       Impact factor: 3.037
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.